Indications |
Oral Hypertension Adult: 40-50 mg daily in divided doses, increased according to response. Max: 200 mg/day. Renal impairment: Reduce dose or prolong dosage interval. Hepatic impairment: Reduce dose or prolong dosage interval. Intravenous Hypertensive crisis Adult: 5-10 mg via slow IV inj, repeated if necessary after 20-30 min. Alternatively, as continuous IV, initial dose is 200-300 mcg/min. Maintenance: 50-150 mcg/min. Special Populations: Dose reduction in renal and hepatic impairment. |
Contraindications |
Severe tachycardia, dissecting aortic aneurysm, heart failure with high cardiac output, cor pulmonale, myocardial insufficiency due to mechanical obstruction, coronary artery disease, idiopathic SLE. Patients with recent MI. |
Warnings / Precautions |
Cerebrovascular disorders. Ischaemic heart disease. Hepatic or renal impairment. May deplete pyridoxine in the body. May impair ability to drive or operate machinery. Monitor for postural hypotension if given to patients with heart failure. Withdraw gradually. CBC and antinuclear antibody tests should be carried out every 6 mth during long-term therapy. Urine analysis is also recommended. Pregnancy and lactation. Daily doses >100 mg may increase the risk of SLE especially in women and slow acetylators. |
Adverse Reactions |
Tachycardia; palpitations; angina pectoris; haemolytic anaemia; paralytic ileus; severe headache; GI disturbances; flushing, dizziness; nasal congestion; peripheral neuropathy with numbness and tingling of extremities; lupus erythematosus-like syndrome; postural hypotension; fluid retention; hepatotoxicity; blood dyscrasias; difficulty in urinating; glomerulonephritis; constipation; depression; anxiety; hypersensitivity reactions; conjunctivitis; lachrymation, tremor; muscle cramps. |
Overdose Reactions |
Symptoms include hypotension, tachycardia, headache and generalised skin flushing. Other complications may include myocardial ischaemia and subsequent MI, cardiac arrhythmia, and profound shock. Treatment is supportive and symptomatic. |
Drug Interactions |
Hypotensives, diazoxide, NSAIDs, oestrogens, sympathomimetics. See Below for More hydralazine Drug Interactions |
Lab Interactions |
May produce positive results in Coomb's test. |
Mechanism of Actions |
Hydralazine is a direct-acting vasodilator which acts predominantly on the arterioles. It reduces BP and peripheral resistance but produces fluid retention. Hydralazine tends to improve renal and cerebral blood flow and its effect on diastolic pressure is more marked than on systolic pressure. Onset: Oral: 45 min. IV: 10-20 min. Duration: Oral and IV: 3-8 hr. Absorption: Rapidly absorbed from the GI tract after oral admin. Distribution: About 90% bound to plasma proteins. Metabolism: Undergoes considerable first-pass metabolism by acetylation in the GI mucosa and liver. Excretion: Mainly excreted in urine as metabolites. |
Administration |
Should be taken with food. |
ATC Classification |
C02DB02 - hydralazine ; Belongs to the class of hydrazinophthalazine derivatives. Used in the treatment of hypertension. |
Available As |
|
Hydralazine
Post Review about Hydralazine Click here to cancel reply.
Hydralazine Containing Brands
Hydralazine is used in following diseases
Drug - Drug Interactions of Hydralazine
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.